The Most Undervalued Healthcare Stock in the S&P 500 Right Now

Bristol Myers Squibb is highlighted as unusually cheap, trading at about 10x forward earnings and 9.9x trailing free cash flow while offering a dividend yield above 4%. Management expects roughly $46 billion to $47.5 billion in 2026 revenue and is targeting $2 billion in annual cost savings by 2027, while newer drugs such as Breyanzi, Camzyos, and Reblozyl are growing quickly. Offset to the bullish setup are ongoing patent-cliff concerns for Revlimid and eventually Eliquis, leaving the stock priced for stagnation despite improving fundamentals.

Analysis

BMY looks less like a value trap and more like a delayed rerating candidate if management can keep the mix shift ahead of the patent cliff. The key second-order effect is that a stabilizing legacy franchise plus growing newer assets can create a much cleaner FCF bridge than the market is modeling, which matters because low-multiple pharma names tend to rerate quickly once investors stop pricing terminal decline and start pricing earnings durability.

The market is likely underestimating how much cost savings can offset the slope of exclusivity-driven erosion over the next 12-24 months. In large-cap pharma, incremental SG&A and manufacturing savings often flow disproportionately to equity value because the revenue base is already high-margin; that means even modest operating leverage can support both dividend safety and buybacks, reducing the chance of multiple compression if growth merely stays positive rather than accelerates.

The real risk is timing asymmetry: near-term upside can be visible on quarterly beats and pipeline headlines, but the stock can still underperform if investors remain focused on the later-stage patent overhang. The market will likely need evidence that newer products can cover a larger share of the decline from the legacy portfolio before awarding a higher multiple, so the catalyst window is months, not days, with the critical checkpoint being whether the growth franchise keeps comping above low-double digits while legacy erosion stays orderly.

Contrarianly, the crowded view is that cheap equals broken here; that may be too simplistic. When a company trades at a depressed FCF multiple despite meaningful cash generation and a credible pipeline, the upside often comes from sentiment normalization rather than fundamental inflection, which can be enough for a 20%-30% move if execution stays intact.

Key Decisions for Investors

• Go long BMY on a 3-6 month horizon, targeting a rerating toward a low-teens forward multiple if newer products continue offsetting legacy decline; downside is limited by cash flow and dividend support, but trim if the next two quarters show growth portfolio deceleration.
• Use a call spread in BMY (e.g., 6-9 month maturity) to express the rerating view with defined risk; this is attractive if you expect headline-driven multiple expansion before the market fully revises earnings assumptions.
• Pair long BMY / short PFE as a relative-value expression: BMY has a cleaner path to FCF stability and a more credible bridge through patent pressure, while the pair reduces sector beta and isolates execution dispersion.
• If holding BMY equity, sell covered calls against a 3-6 month position; the stock is likely to grind higher rather than trend sharply, and implied volatility should be monetizable while waiting for pipeline catalysts.
• Set a tactical stop if management commentary implies the cost-savings program is slipping beyond 2027 or if growth portfolio momentum falls below low-double-digit growth for two consecutive quarters, because the valuation case depends on execution rather than narrative alone.